Nabla

Boston, United States Founded: 2020 • Age: 6 yrs
Synthetic biology platform for functional protein identification is provided.

About Nabla

Nabla is a Healthcare company based in Boston (United States) founded in 2020 by Frances Anastassacos and Surge Biswas. Synthetic biology platform for functional protein identification is provided. It operates on a AI-as-a-Service and Professional Services model. Nabla has raised $37 million across 3 funding rounds from investors including Khosla Ventures, Radical Ventures and Zetta Venture Partners. Its chief executive, as recorded, is Surge Biswas. Nabla offers products and services including Antibody Design Platform. Its focus areas include Biotechnology and Drug Discovery. Its legal entity is Nabla Bio, Inc.

Company details

Nabla is engaged in developing integrated AI and experimental technologies for drug design. The company is based in Cambridge, MA, and focuses on creating generative models and multiplexed screens for antibody design. Solutions are targeted at challenging disease targets like GPCRs and ion channels. Partnerships with leading pharmaceutical companies are established to maximize impact. The integration of AI-guided design with wet-lab experimentation is emphasized to enhance manufacturability, safety, and efficacy of drugs for complex diseases.

  • Headquarters Boston, United States
  • Founders Frances Anastassacos, Surge Biswas
  • Sectors
    Healthcare
  • Website nabla.bio
  • Social LinkedIn X
  • Legal Name Nabla Bio, Inc
Key Metrics
  • Total Equity Funding
    $37M (USD)

    in 3 rounds

  • Latest Funding Round
    $26M (USD), Series A

    May 2024

  • Investors

Products & Services of Nabla

Nabla offers a comprehensive portfolio of products and services, including Antibody Design Platform.

Antibody Design Platform
Biotechnology

Antibodies are designed with AI and experimental technologies.

Funding Insights of Nabla

Nabla has successfully raised a total of $37M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $26 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $37M
  • Total Rounds 3
  • Last Round Series A β€” $26M
  • First Round $256,000

    (Apr 2021)

  • Investors Count 6

All 3 funding rounds of Nabla with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2024$26MSeries A–Radical Ventures
–
Dec 2021$11MSeed–Khosla Ventures, Zetta Venture Partners
Apr 2021$256,000Grant––
Valuation history

6 investors in total: 6 institutional.

Investors in Nabla

Nabla has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, Radical Ventures and Zetta Venture Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on AI-driven companies
radical.vcToronto, Canada
Early-stage startups are funded by this venture capital firm.
2004khoslaventures.comMenlo Park, United States
Seed and early-stage tech investments are made in the US.
zettavp.comSan Francisco, United States
Venture capital firm focused on multiple sectors
fiftyyears.comSan Francisco, United States
Seed stage tech-focused VC firm investing primarily in the US
cantos.vcSan Francisco, United States
A government-backed foundation providing seed-stage investments to support small businesses.
1950nsf.govArlington, United States
Premium access

Investor details for Nabla

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Nabla

8 people are tracked at Nabla (2 in leadership, 6 in team).

NameRoleGroup
Frances Anastassacos
Co-FounderLeadership
Surge Biswas
Co-Founder & CEOLeadership
Mark Desimone
ScientistTeam
Bridget Li
ML Scientist ITeam
Sunita Subramanian
Senior ScientistTeam
Vinicius Reis
Senior ML ScientistTeam
Connor Blankenship
Senior ScientistTeam
Adithya Paramasivam
ML ScientistTeam
Premium access

Complete people profiles for Nabla

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Nabla

3 dated milestones of Nabla across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nabla is founded.
  2. Funding First funding round of $256K.
  3. Funding Latest funding round, Series A, of $26.0M.

Web traffic of Nabla

The website of Nabla (nabla.bio) receives about 8.2K visits a month.

  • Monthly visits
    8.2K

    ▼ 3% vs previous month

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Nabla (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nabla

Premium access

Complete news archive for Nabla

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nabla

Nabla was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Nabla is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Surge Biswas is the CEO of Nabla, as recorded in our data. They have also founded this company.

Nabla is a funded company, having raised a total of $37M across 3 funding rounds to date. The company's 1st funding round was a Grant of $256K, raised on Apr 2021.

Nabla is engaged in developing integrated AI and experimental technologies for drug design. The company is based in Cambridge, MA, and focuses on creating generative models and multiplexed screens for antibody design. Solutions are targeted at challenging disease targets like GPCRs and ion channels. Partnerships with leading pharmaceutical companies are established to maximize impact. The integration of AI-guided design with wet-lab experimentation is emphasized to enhance manufacturability, safety, and efficacy of drugs for complex diseases.

Nabla offers Antibody Design Platform.

Nabla has 6 investors. Key investors include Khosla Ventures, Radical Ventures, Zetta Venture Partners, Fifty Years, and Cantos Ventures.

Nabla operates through Nabla Bio, Inc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available